+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The self-expanding Symetis Acurate does not increase cerebral microembolic load when compared to the balloon-expandable Edwards Sapien prosthesis: a transcranial Doppler study in patients undergoing transapical aortic valve implantation



The self-expanding Symetis Acurate does not increase cerebral microembolic load when compared to the balloon-expandable Edwards Sapien prosthesis: a transcranial Doppler study in patients undergoing transapical aortic valve implantation



Plos one 9(10): E108191



The aim of this study was to quantify potential differences in count, frequency and pattern of high-intensity transient signals (HITS) during transapical transcatheter aortic valve implantation (TA-TAVI), by comparing the Symetis Acurate TA (SA) with the balloon-expandable Edwards Sapien XT (ES) system. Recently, the Symetis Acurate TA revalving system has been introduced for TA-TAVI. The Symetis Acurate TA aortic bioprosthesis is self-expanding and is deployed by a specific two-step implantation technique. Whether this novel method increases the load of intraprocedural emboli, detected by transcranial Doppler ultrasound (TCD) as HITS, or not is not clear. Twenty-two patients (n = 11 in each study arm, median logistic EuroScore 20%, median STS score 7%) displayed continuous TCD signals of good quality throughout the entire TA-TAVI procedure and were included in the final analysis. Data are presented as median with interquartile ranges. No significant differences were detected in total procedural or interval-related HITS load (SA: 303 [200; 594], ES: 499 [285; 941]; p = 0.16). With both devices, HITS peaked during prosthesis deployment (PD), whereas significantly fewer HITS occurred during instrumentation (SA: p = 0.002; ES: < 0.001) or post-implantation PI (SA: p = 0.007; ES: < 0.001). PD-associated HITS amounted to almost half of the total HITS load. One patient suffered new disabling stroke at 30 days. Thirty-day mortality amounted to 13.6% (3 of 22 patients). Simplified transapical delivery using the self-expanding SA device does not increase HITS, despite of a two-step deployment technique with more interactions with the native aortic valve, when compared to the balloon-expandable ES valve. The similarity in HITS count, frequency and pattern with the two systems suggests a common mechanism for the release of cerebral microemboli.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 056494432

Download citation: RISBibTeXText

PMID: 25289688


Related references

The balloon-expandable Edwards Sapien 3 valve is superior to the self-expanding Medtronic CoreValve in patients with severe aortic stenosis undergoing transfemoral aortic valve implantation. Journal of Cardiology 69(6): 877-882, 2017

Transapical aortic valve implantation using a Symetis Acurate self-expandable bioprosthesis: initial outcomes of 10 patients. Wideochirurgia i Inne Techniki Maloinwazyjne 12(2): 172-177, 2017

TCT-630 Transfemoral aortic valve implantation (TAVI) with the balloon-expandable Edwards Sapien 3 valve compared with the self-expanding Medtronic CoreValve. Journal of the American College of Cardiology 66(15): B257-B258, 2015

Symetis Acurate aortic valve-in-valve implantation for early degeneration of a Sapien THV prosthesis. Annals of Thoracic Surgery 96(5): 1880, 2013

Transapical transcatheter aortic valve implantation using the second-generation self-expanding Symetis ACURATE TA valve. Multimedia Manual of Cardiothoracic Surgery 2014:, 2014

Clinical outcome and paravalvular leakage of the new balloon-expandable Edwards Sapien 3 valve in comparison to its predecessor model (Edwards Sapien XT) in patients undergoing transfemoral aortic valve replacement. Catheterization and Cardiovascular Interventions 88(3): 466-475, 2016

Outcome With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Valve in Patients Undergoing Transfemoral Aortic Valve Replacement. Circulation. Cardiovascular Interventions 10(6):, 2017

Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve. International Journal of Cardiology 195: 171-175, 2015

TCT-663 Twelve months outcome in patients undergoing transfemoral aortic valve replacement (TAVR) with the repositionable and retrievable Boston Scientific Lotus valve compared with the balloon-expandable Edwards Sapien 3 device. Journal of the American College of Cardiology 68(18): B268-B269, 2016

TCT-643 Platelet activation is less enhanced in the new balloon expandable Edwards Sapien 3 valve compared to its predecessor model (Edwards Sapien XT) and is associated to the extent of residual aortic regurgitation. Journal of the American College of Cardiology 66(15): B262-B263, 2015

Rationale and design of the Edwards SAPIEN-3 periprosthetic leakage evaluation versus Medtronic CoreValve in transfemoral aortic valve implantation (ELECT) trial : A randomised comparison of balloon-expandable versus self-expanding transcatheter aortic valve prostheses. Netherlands Heart Journal 25(5): 318-329, 2017

Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Versus the Balloon-Expandable SAPIEN XT Valve. American Journal of Cardiology 117(9): 1502-1510, 2016

Transcatheter aortic valve implantation for high risk patients with severe aortic stenosis using the Edwards Sapien balloon-expandable bioprosthesis: a single centre study with immediate and medium-term outcomes. Catheterization and Cardiovascular Interventions 75(4): 475-485, 2010

Emergency transfemoral aortic valve-in-valve implantation with the balloon-expandable Edwards-Sapien valve. Journal of Cardiovascular Medicine 10(12): 936-939, 2009

Transfemoral valve-in-valve implantation for degenerated bioprosthetic aortic valves using the new balloon-expandable Edwards Sapien 3 valve. Catheterization and Cardiovascular Interventions 88(4): 636-643, 2016